Clinical Trial Update: A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression [Phase 2]

View source ↗

Summary

Phase II randomized trial of LEE011 (novartis) in relapsed/refractory, incurable teratoma with progression completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Teratoma

Drugs mentioned

• LEE011 (ribociclib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Teratoma | Phase 2 | Status: COMPLETED | Results posted: 2020-10-26